Naha kuring kedah ngamimitian pamariksaan kanker kolor dina 45?

Bagikeun Post Ieu

A new study reported at the European Digestive Disease Week (UEG) shows that regardless of family history, colorectal cancer screening has doubled since the age of 45 rather than 50. (UEG 2017)

Panaliti nunjukkeun yén populasi umum program panyaringan kolonoskopi nyarankeun saringan pikeun jalma anu umurna langkung ti 50 taun, tapi kajadian kanker koloréktal dina yuswa 50 taun parantos ningkat.

Panilitian prospektif ieu ngaevaluasi 6027 kasus kolonoskopi. Tingkat deteksi polip, adenomas, polip ageung sareng kanker masing-masing 34.0%, 32.0%, 8.0% sareng 3.6%. Salah sahiji papanggihan anu langkung penting dina panilitian ieu nyaéta nalika résiko adénoma sareng deteksi kanker dianalisis ku kelompok umur anu béda, tingkat deteksi jalma anu sahandapeun 30 taun lemah pisan, sareng éta relatif handap sateuacan umur 45 taun. Aya kanaékan anu penting pisan.

Rata-rata tingkat deteksi polip 4438 pasien langkung ti 50 taun langkung ti 35%, sareng tingkat deteksi kanker langkung ti 5%. Rata-rata tingkat deteksi polip 515 pasien umur 45-49 taun 26%, sareng tingkat deteksi kanker ampir 4%. Tingkat deteksi 1076 mata pelajaran ≤44 taun kalintang handap. Malah saatos ngiringan populasi anu berisiko tinggi sareng riwayat kulawarga, tingkat deteksi polip atanapi kanker masih luhur diantara jalma umur 45 dugi 49 taun.

The researchers believe that the research population is a real practice population, so the research conclusions are applicable to the general screening population. 50-year-old should not be used as the starting age for screening, and kangker colorectal screening should be started from 45-year-old to better prevent colorectal cancer. The results of the study suggest that, even if there is no family history, the risk of disease will increase greatly after the age of 45, which is more critical. 

Ngalanggan Pikeun Newsletter kami

Meunang apdet sarta pernah sono blog ti Cancerfax

Langkung Kanggo Ngajalajah

Ngartos BCMA: Target Revolusioner dina Pangobatan Kanker
Kanker getih

Ngartos BCMA: Target Revolusioner dina Pangobatan Kanker

Bubuka Dina realm kantos-ngembang perlakuan onkologis, élmuwan persistently neangan kaluar target unconventional nu bisa amplify efektivitas interventions bari mitigating repercussions nu teu dihoyongkeun.

Peryogi bantosan? Tim kami siap ngabantosan anjeun.

Kami ngarepkeun pamulihan gancang tina anu anjeun sayogi sareng anu caket.

Mimitian obrolan
Kami Online! Ngobrol Jeung Kami!
Scan kode na
Halo,

Wilujeng sumping di CancerFax!

CancerFax mangrupikeun platform pioneering anu didedikasikeun pikeun ngahubungkeun individu anu nyanghareupan kanker tahap lanjut kalayan terapi sél anu inovatif sapertos terapi CAR T-Cell, terapi TIL, sareng uji klinis di sakuliah dunya.

Hayu urang nyaho naon bisa urang pigawé pikeun anjeun.

1) Pangobatan kanker di luar negeri?
2) Terapi T-Sél mobil
3) Vaksin kanker
4) Konsultasi video online
5) Terapi proton